Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.60 (
caspase-7
)
920
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
STAT1
is a transcription factor that plays a crucial role in signaling by interferons (IFNs). In this study we demonstrated that inhibitors of histone deacetylase (HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activation,
STAT1
phosphorylation, its nuclear translocation, and
STAT1
-dependent gene activation. Furthermore, we showed that silencing of HDAC1, HDAC2, and HDAC3 through RNA interference markedly decreased IFNgamma-driven gene activation and that overexpression of HDAC1, HDAC2, and HDAC3 enhanced
STAT1
-dependent transcriptional activity. Our data therefore established the essential role of deacetylase activity in
STAT1
signaling. Induction of IRF-1 by IFNgamma requires functional
STAT1
signaling and was abrogated by butyrate, trichostatin A, suberoylanilide hydroxamic acid, and
STAT1
small interfering RNA. In contrast, silencing of
STAT1
did not interfere with IFNgamma-induced expression of STAT2 and
caspase-7
, and HDAC inhibitors did not preclude IFNgamma-induced expression of
STAT1
, STAT2, and
caspase-7
, suggesting that HDAC inhibitors impede the expression of IFNgamma target genes whose expression depends on
STAT1
but do not interfere with
STAT1
-independent signaling by IFNgamma. Finally, we showed that inhibitors of deacetylase activity sensitized colon cancer cells to IFNgamma-induced apoptosis through cooperative negative regulation of Bcl-x expression, demonstrating that interruption of the balance between
STAT1
-dependent and
STAT1
-independent signaling significantly alters the biological activity of IFNgamma.
...
PMID:Requirement of histone deacetylase activity for signaling by STAT1. 1512 34